HRP20250206T1 - 3-sulfopropanska kiselina za liječenje neurodegenerativnih poremećaja - Google Patents
3-sulfopropanska kiselina za liječenje neurodegenerativnih poremećaja Download PDFInfo
- Publication number
- HRP20250206T1 HRP20250206T1 HRP20250206TT HRP20250206T HRP20250206T1 HR P20250206 T1 HRP20250206 T1 HR P20250206T1 HR P20250206T T HRP20250206T T HR P20250206TT HR P20250206 T HRP20250206 T HR P20250206T HR P20250206 T1 HRP20250206 T1 HR P20250206T1
- Authority
- HR
- Croatia
- Prior art keywords
- subject
- spa
- pharmaceutically acceptable
- need
- prevention
- Prior art date
Links
- OURSFPZPOXNNKX-UHFFFAOYSA-N 3-sulfopropanoic acid Chemical compound OC(=O)CCS(O)(=O)=O OURSFPZPOXNNKX-UHFFFAOYSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713061P | 2018-08-01 | 2018-08-01 | |
| EP19752795.5A EP3829563B1 (en) | 2018-08-01 | 2019-07-30 | 3-sulfopropanoic acid for treating neurodegenerative disorders |
| PCT/US2019/044023 WO2020028290A1 (en) | 2018-08-01 | 2019-07-30 | Methods for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250206T1 true HRP20250206T1 (hr) | 2025-04-11 |
Family
ID=67614642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250206TT HRP20250206T1 (hr) | 2018-08-01 | 2019-07-30 | 3-sulfopropanska kiselina za liječenje neurodegenerativnih poremećaja |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12083082B2 (https=) |
| EP (1) | EP3829563B1 (https=) |
| JP (1) | JP7573512B2 (https=) |
| KR (1) | KR102716959B1 (https=) |
| CN (1) | CN112867485A (https=) |
| AU (1) | AU2019315853B2 (https=) |
| BR (1) | BR112021001739A2 (https=) |
| CL (1) | CL2021000269A1 (https=) |
| DK (1) | DK3829563T3 (https=) |
| EA (1) | EA202190406A1 (https=) |
| ES (1) | ES3011716T3 (https=) |
| FI (1) | FI3829563T3 (https=) |
| HR (1) | HRP20250206T1 (https=) |
| HU (1) | HUE070101T2 (https=) |
| IL (1) | IL280424B2 (https=) |
| LT (1) | LT3829563T (https=) |
| MX (1) | MX2021001287A (https=) |
| MY (1) | MY206530A (https=) |
| PH (1) | PH12021550213A1 (https=) |
| PL (1) | PL3829563T3 (https=) |
| PT (1) | PT3829563T (https=) |
| RS (1) | RS66516B1 (https=) |
| SG (1) | SG11202100767XA (https=) |
| SI (1) | SI3829563T1 (https=) |
| SM (1) | SMT202500080T1 (https=) |
| UA (1) | UA130011C2 (https=) |
| WO (1) | WO2020028290A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025504A2 (pt) * | 2019-06-17 | 2022-04-26 | Alzheon Inc | Métodos para tratar distúrbios neurodegenerativos |
| MX2024007070A (es) * | 2021-12-09 | 2024-08-22 | Alzheon Inc | Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| PT2089417E (pt) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico |
| WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
| WO2014121083A1 (en) | 2013-01-31 | 2014-08-07 | President And Fellows Of Harvard College | Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition |
| CA2941415A1 (en) * | 2014-03-21 | 2015-09-24 | Alzheon, Inc. | Methods for treating neurological disorders |
| FI3347002T3 (fi) | 2015-09-10 | 2023-08-10 | Alzheon Inc | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa |
-
2019
- 2019-07-30 JP JP2021505721A patent/JP7573512B2/ja active Active
- 2019-07-30 HU HUE19752795A patent/HUE070101T2/hu unknown
- 2019-07-30 SG SG11202100767XA patent/SG11202100767XA/en unknown
- 2019-07-30 FI FIEP19752795.5T patent/FI3829563T3/fi active
- 2019-07-30 CN CN201980064415.6A patent/CN112867485A/zh active Pending
- 2019-07-30 SM SM20250080T patent/SMT202500080T1/it unknown
- 2019-07-30 US US17/264,477 patent/US12083082B2/en active Active
- 2019-07-30 EA EA202190406A patent/EA202190406A1/ru unknown
- 2019-07-30 EP EP19752795.5A patent/EP3829563B1/en active Active
- 2019-07-30 BR BR112021001739-9A patent/BR112021001739A2/pt unknown
- 2019-07-30 RS RS20250164A patent/RS66516B1/sr unknown
- 2019-07-30 PT PT197527955T patent/PT3829563T/pt unknown
- 2019-07-30 AU AU2019315853A patent/AU2019315853B2/en active Active
- 2019-07-30 WO PCT/US2019/044023 patent/WO2020028290A1/en not_active Ceased
- 2019-07-30 IL IL280424A patent/IL280424B2/en unknown
- 2019-07-30 KR KR1020217005803A patent/KR102716959B1/ko active Active
- 2019-07-30 MY MYPI2021000515A patent/MY206530A/en unknown
- 2019-07-30 DK DK19752795.5T patent/DK3829563T3/da active
- 2019-07-30 LT LTEPPCT/US2019/044023T patent/LT3829563T/lt unknown
- 2019-07-30 ES ES19752795T patent/ES3011716T3/es active Active
- 2019-07-30 PL PL19752795.5T patent/PL3829563T3/pl unknown
- 2019-07-30 SI SI201930898T patent/SI3829563T1/sl unknown
- 2019-07-30 HR HRP20250206TT patent/HRP20250206T1/hr unknown
- 2019-07-30 MX MX2021001287A patent/MX2021001287A/es unknown
- 2019-07-30 UA UAA202101015A patent/UA130011C2/uk unknown
-
2021
- 2021-01-28 PH PH12021550213A patent/PH12021550213A1/en unknown
- 2021-02-01 CL CL2021000269A patent/CL2021000269A1/es unknown
-
2024
- 2024-08-02 US US18/793,452 patent/US20250213507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kauffman et al. | Antipyretic efficacy of ibuprofen vs acetaminophen | |
| HRP20250206T1 (hr) | 3-sulfopropanska kiselina za liječenje neurodegenerativnih poremećaja | |
| JP2019529541A5 (https=) | ||
| JP6789579B2 (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| JP2015524484A5 (https=) | ||
| JP2013517300A5 (https=) | ||
| JP2002527474A (ja) | 躁病および双極性障害の治療法 | |
| JP2021535152A5 (https=) | ||
| Al-Mosawi | The pattern of pervasive developmental disorders in Iraqi children | |
| BR112023016319A2 (pt) | Anticorpos anti-beta amiloide e usos dos mesmos | |
| Choi et al. | Perverted head-shaking and positional downbeat nystagmus in pregabalin intoxication | |
| IE914568A1 (en) | Use of acetyl L-carnitine in the therapeutic treatment of coma | |
| CA2932791A1 (en) | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder | |
| CN119212690A (zh) | 包含meai和n-酰基乙醇胺的组合物及其用途 | |
| Rinkel et al. | Prevention and treatment of medical and neurological complications in patients with aneurysmal subarachnoid haemorrhage | |
| MA45202A1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| WO2005019474A3 (en) | Human autism susceptibility gene and uses thereof | |
| KR20160030206A (ko) | 사구체 질환을 치료하는데 사용하기 위한 로스마피모드 | |
| WO2006003520A3 (en) | Human autism predisposition gene encoding a transcription factor and uses thereof | |
| MA30662B1 (fr) | Derives de phenyl-prenyl-ether pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux | |
| MA30661B1 (fr) | Derives de n-phenyl-prenylamine pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux. | |
| WO2006087634A3 (en) | Uses of human autism susceptibility gene encoding a kinase | |
| US20220249427A1 (en) | Anavex2-73 for the treatment of genetic neurodevelopmental disorders | |
| Chand et al. | Understanding a strange phenomenon: Lilliputian hallucinations | |
| MA29329B1 (fr) | Derives d'amide en tant que ligands de canal ionique, compositions pharmaceutiques et methodes d'utilisation associees |